Heart failure is a serious condition where the heart cannot pump enough blood to meet the body's needs. For many people, this happens even when the heart muscle squeezes normally, a condition known as heart failure with preserved ejection fraction. This study looked at a wide range of common heart medications to see which ones actually help people live longer or feel better. The researchers wanted to know if taking these drugs could stop the disease from getting worse or if some were just a waste of money.
The team looked at data from 48,235 patients who had been prescribed various medicines. These drugs included common ones like beta blockers and ACE inhibitors, as well as newer options like GLP-1 receptor agonists and SGLT2 inhibitors. The study compared these treatments against taking a placebo, which is an inactive pill used to see if the drug itself is doing the work. The main goal was to see if these medicines could lower the risk of a major heart event or a trip to the hospital.
The results showed clear winners for specific goals. Patients taking GLP-1 receptor agonists had a 27% lower risk of dying from heart causes or being hospitalized for heart failure compared to those on a placebo. Similarly, SGLT2 inhibitors lowered that same risk by about 21%. Beyond just survival, these drugs also helped patients walk further. Those on GLP-1 receptor agonists walked an average of 17.6 meters further than those on a placebo, while their quality of life scores improved by an average of 7.4 points.
However, the study did not find a difference in overall death rates. None of the drugs studied, including the new ones, showed a statistically significant reduction in all-cause mortality. This means that while the drugs helped prevent hospital visits and improved daily function, they did not necessarily extend life expectancy on their own. Additionally, the researchers did not report any safety data, such as side effects or how well patients tolerated the new medications, which is a significant gap in the information.
It is important not to get too excited about these findings. This was a review of existing data, not a new trial where patients were specifically assigned to take these drugs. Because safety information was missing, doctors cannot yet say these new drugs are safe for everyone. Patients should not stop or start any medication based on this single study. The best approach is to talk with a doctor about the full picture of your heart health and the specific risks and benefits of any treatment plan.